What is the P/E ratio of Fresenius Kabi Oncology?

The latest standalone P/E ratio of Fresenius Kabi Oncology as of 01-Jan-1970 is 0.00.

What is the P/B ratio of Fresenius Kabi Oncology?

The latest standalone P/B ratio of Fresenius Kabi Oncology as of 01-Jan-1970 is 3.87.

Fresenius Kabi Oncology Ltd - Stock Valuation and Financial Performance

Name: Fresenius Kabi Oncology
Brand: Fresenius Kabi Oncology

BSE: 532545 | NSE: FKONCO | Pharmaceuticals & Drugs | Small Cap

Place order

BSE Share Price
Not Listed

DeciZen - make an informed investing decision on Fresenius Kabi Oncol

Based on:

Data

M-Cap below 100cr DeciZen not available

Fresenius Kabi Oncology stock performance -

PE Chart Key Ratios

P/E Ratio (SA):

0.00

Market Cap:

2,254.9 Cr.

52-wk low:

132

52-wk high:

132.6

Is an attractive stock to invest in?

1. Is a good quality company?

Data is not available for this company.

2. Is undervalued or overvalued?

No data found

3. Is a good buy now?

No data found

10 Year X-Ray of Fresenius Kabi Oncol:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	TTM
ROCE % ⓘ	14.5%	-13.1%	-14.9%	-8.1%	4.3%	6.8%	-2.7%	4.6%	-40.5%	6.7%	-
Value Creation Index ⓘ	0.0	-1.9	-2.1	-1.6	-0.7	-0.5	-1.2	NA	NA	NA	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	596	408	464	542	624	703	660	630	603	667	660
Sales YoY Gr.	-	-31.6%	13.7%	16.7%	15.2%	12.7%	-6.2%	-4.5%	-4.3%	10.7%	-
Adj EPS ⓘ	5.4	-6.4	-9.3	-3.4	0.2	2.9	0.8	2.5	-4.6	1	-3.2
YoY Gr.	-	-219.1%	NA	NA	NA	1731.3%	-73.7%	224.7%	-282.4%	NA	-
BVPS (₹) ⓘ	42.6	35.5	30.7	25.9	25.8	26.9	23.9	23.9	3.5	25.6	34.3
Adj Net Profit ⓘ	85.4	-102	-159	-57	2.8	49.8	13.1	41.3	-75.3	49.6	-54
Cash Flow from Ops. ⓘ	127	-52.7	-121	7.9	-39.1	112	98.4	77	0	-460	-
Debt/CF from Ops. ⓘ	1.1	-5.9	-2.9	53.1	-13.3	4.3	4.7	6.2	32629.1	-0.1	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	1.3%	1.4%	0.4%	10.7%
Adj EPS ⓘ	-16.8%	45.1%	10.2%	NA
BVPSⓘ	-5.5%	-0.1%	2.3%	623.7%
Share Price	-	-	-	-

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	TTM
Return on Equity % ⓘ	13.5	-16.5	-29.3	-11.9	0.6	11.1	3	10.3	-33.2	7.7	-10.6
Op. Profit Mgn % ⓘ	24	-18.2	-20.6	1.1	13.9	19.1	13.8	14.8	13.6	14.8	-16.5
Net Profit Mgn % ⓘ	14.3	-24.9	-34.2	-10.5	0.4	7.1	2	6.6	-12.5	7.4	-8.2
Debt to Equity ⓘ	0.2	0.6	0.7	1	1.2	1	1.1	1.2	10.2	0	-
Working Cap Days ⓘ	353	575	523	438	409	427	473	507	574	604	305
Cash Conv. Cycle ⓘ	170	267	214	198	185	176	168	160	221	265	156

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Net Profit has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Fresenius Kabi Oncology Ltd.

	Standalone	Consolidated
TTM EPS (₹)	-3.2	0.9
TTM Sales (₹ Cr.)	660	516
BVPS (₹.) ⓘ	34.3	15.6
Reserves (₹ Cr.) ⓘ	566	248
P/BV ⓘ	3.87	8.50
PE ⓘ	0.00	140.86

From the Market
52 Week Low / High (₹)	132.00 / 132.60
All Time Low / High (₹)	27.05 / 193.75
Market Cap (₹ Cr.)	2,255
Equity (₹ Cr.)	17
Face Value (₹)	1
Industry PE ⓘ	43

Management X-Ray of Fresenius Kabi Oncol:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Fresenius Kabi Oncol

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Fresenius Kabi Oncol

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22
Sales	596.30	408.17	464.14	541.56	624.01	703.48	659.57	629.87	602.59	667.27
Operating Expenses ⓘ	453.30	484.04	559.88	553.36	539.64	572.43	569.14	545.94	524.13	588.60
Manufacturing Costs	157.26	177.91	180.18	86.54	85.18	75.96	75.56	72	65.80	60.62
Material Costs	164.96	156.77	228.23	241.68	251.71	273.60	269.24	243.47	228.65	282.10
Employee Cost	67.80	69	78.16	115.61	124.43	143.21	143.47	148.39	163.60	161.53
Other Costs ⓘ	63.28	80.36	73.31	109.53	78.32	79.67	80.87	82.08	66.07	84.34
Operating Profit ⓘ	143	-75.87	-95.73	-11.80	84.38	131.05	90.43	83.93	78.46	78.67
Operating Profit Margin (%)	24.0%	-18.6%	-20.6%	-2.2%	13.5%	18.6%	13.7%	13.3%	13.0%	11.8%
Other Income ⓘ	1.80	8.55	52.55	12.77	11.65	28.20	41.88	36.24	36.23	38.12
Interest ⓘ	-2.60	12.59	24.56	29.21	36.63	45.86	36.80	39.89	37.31	16.45
Depreciation ⓘ	25.79	30.89	44.31	52.10	48.71	54.83	54.62	57.86	53.77	53.01
Exceptional Items ⓘ	-6.81	-12.44	-42.20	-18.62	-8.54	-40.13	-102.23	-22.57	-369.41	0
Profit Before Tax ⓘ	114.81	-123.26	-154.25	-98.95	2.15	18.42	-61.33	-0.15	-345.79	47.32
Tax ⓘ	34.22	-11.90	2.86	-16.34	4.57	-1.16	-7.41	-19.29	-9.63	11.76
Profit After Tax	80.59	-111.35	-157.12	-82.62	-2.42	19.58	-53.92	19.14	-336.16	35.56
PAT Margin (%)	13.5%	-27.3%	-33.9%	-15.3%	-0.4%	2.8%	-8.2%	3.0%	-55.8%	5.3%
Adjusted EPS (₹)	5.1	-7.0	-9.2	-4.9	-0.1	1.2	-3.2	1.2	-20.3	0.7
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22
Equity and Liabilities
Shareholders Fund	673.18	561.83	522.20	440.53	438.35	458.17	406.84	395.64	58.53	1,230.69
Share Capital ⓘ	15.82	15.82	17.02	17.02	17.02	17.02	17.02	16.52	16.52	48.04
Reserves ⓘ	657.36	546	505.17	423.51	421.33	441.15	389.82	379.12	42.01	1,182.65
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	140.16	310.69	349.48	421.25	520.80	474.47	462.87	476.50	395.85	29
Long Term Debt	95.22	121.39	98.67	170.38	308.46	308.46	308.46	308.46	139.46	29
Short Term Debt	44.94	189.30	250.82	250.86	212.34	166.01	154.41	168.04	256.39	0
Trade Payables	91.36	186.60	196.88	197.60	160.89	163.96	222.22	240.89	258.14	252.17
Others Liabilities ⓘ	249.95	167.20	175.97	119.56	227.40	263.34	262.38	223.63	721.50	164.08
Total Liabilities ⓘ	1,154.66	1,226.32	1,244.54	1,178.94	1,347.43	1,359.94	1,354.31	1,336.65	1,434.02	1,675.94
Fixed Assets
Gross Block	460.52	596.28	662.53	574.38	594.83	641.47	686.62	687.64	715.41	760.03
Accumulated Depreciation	108.79	133.60	179.15	52.03	100.57	172.75	230.14	267.82	314.31	357.28
Net Fixed Assetsⓘ	351.74	462.68	483.38	522.35	494.26	468.72	456.48	419.83	401.09	402.75
CWIP ⓘ	163.07	78.99	55.20	30.39	44.64	37.55	37.02	24.83	25.17	38.78
Investmentsⓘ	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
Inventories	245.09	324.55	340.18	384.41	399.50	382.23	386.01	439.13	471.51	510.39
Trade Receivables	185.08	111.43	118.02	133.33	142.74	162.16	149.27	153.96	223.59	355.49
Cash Equivalents	0.49	1.76	0.85	2.34	8.26	1.64	1.97	0.78	4.83	30.14
Others Assetsⓘ	209.16	246.88	246.88	106.10	257.99	307.62	323.54	298.10	307.80	338.37
Total Assets ⓘ	1,154.66	1,226.32	1,244.54	1,178.94	1,347.43	1,359.94	1,354.31	1,336.65	1,434.02	1,675.94

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22
Cash Flow From Operating Activity ⓘ	127.41	-52.73	-121.48	7.93	-39.12	111.63	98.41	77.01	0.02	-459.75
PBT ⓘ	114.81	-123.26	-154.25	-98.95	2.15	18.42	-61.33	-0.15	-345.79	47.32
Adjustment ⓘ	22.89	65.83	22.93	88.39	69.59	119.31	96.51	114.15	103.05	61.95
Changes in Working Capital ⓘ	17.48	16.4	10.09	18.69	-110.48	-19.82	66.68	-36.94	242.83	-568.87
Tax Paid ⓘ	-27.77	-11.70	-0.24	-0.20	-0.37	-6.28	-3.46	-0.06	-0.07	-0.15
Cash Flow From Investing Activity ⓘ	-120.42	-85.58	-44.06	-39.16	-32.69	-28.03	-52.21	-46.24	-44.58	-58.89
Capex	-120.82	-77.54	-36.90	-36.88	-39.51	-36.85	-54.47	-45.54	-49.39	-59.88
Net Investments	0	-8.12	-7.95	0	10.22	1.08	1.48	-0.10	2.69	-0.04
Others ⓘ	0.40	0.08	0.79	-2.28	-3.40	7.74	0.78	-0.61	2.12	1.03
Cash Flow From Financing Activityⓘ	-19.61	139.52	164.28	-47.58	147.43	-29	-10.05	-32.97	49.12	556.14
Net Proceeds from Shares ⓘ	0	0	119	0	0	0	0	0	0	1,134.70
Net Proceeds from Borrowing ⓘ	0	0	0	60	138.08	0	0	0	29	-308.46
Interest Paid ⓘ	-12.46	-6.14	-23	-28.58	-30.65	-37	-33.05	-36.23	-32.48	-18.98
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-7.15	145.66	68.28	-79	40	8	23	3.25	52.59	-251.13
Net Cash Flow ⓘ	-12.63	1.21	-1.26	-78.81	75.62	54.60	36.14	-2.21	4.56	37.50

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22
Ratios
ROE (%)	12.73	-18.03	-28.99	-17.16	-0.55	4.37	-12.47	4.77	-148.03	5.52
ROCE (%)	14.45	-13.13	-14.87	-8.05	4.26	6.8	-2.72	4.56	-40.47	6.67
Asset Turnover Ratio	0.57	0.35	0.39	0.46	0.5	0.52	0.49	0.47	0.44	0.43
PAT to CFO Conversion(x)	1.58	N/A	N/A	N/A	N/A	5.7	N/A	4.02	N/A	-12.93
Working Capital Days
Receivable Days	115	129	86	83	79	79	86	88	114	158
Inventory Days	128	248	250	239	225	202	213	239	276	269
Payable Days	205	324	293	274	249	217	262	347	398	330

Fresenius Kabi Oncology Ltd Stock News

Fresenius Kabi Oncology Ltd FAQs

What is the share price of Fresenius Kabi Oncol?

Company share prices are keep on changing according to the market conditions. The closing price of Fresenius Kabi Oncol on 01-Jan-1970 05:30 is ₹0.00.

What is the market cap of Fresenius Kabi Oncol?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Fresenius Kabi Oncol stood at ₹2,254.9.

What is the P/E ratio of Fresenius Kabi Oncol?

The latest P/E ratio of Fresenius Kabi Oncol as of 01-Jan-1970 05:30 is 0.00.

What is the P/B ratio of Fresenius Kabi Oncol?

The latest P/B ratio of Fresenius Kabi Oncol as of 01-Jan-1970 05:30 is 3.87.

What is the 52-week high and low of Fresenius Kabi Oncol?

The 52-week high of Fresenius Kabi Oncol is ₹132.6 and the 52-week low is ₹132.0.

What is the TTM revenue of Fresenius Kabi Oncol?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Fresenius Kabi Oncol is ₹659.6 ( Cr.) .

About Fresenius Kabi Oncology Ltd

Dabur Pharma, a leading company for cancer research and oncology drugs, was renamed Fresenius Kabi Oncology after its acquisition by Fresenius Kabi, the leader in infusion therapy and clinical nutrition in Europe, Latin America, Asia Pacific as well as in the US, where it is a leading supplier of IV generic drugs.

The company markets its products to various part of world namely Bangladesh, Sri Lanka, Thailand, Philippines, Malaysia, Vietnam, Myanmar, Jordan, Russia, Ukraine, Georgia, Kazakhstan, Uzbekistan, Hungary, Kenya, Nigeria, Ghana, Zimbabwe, Brazil, Venezuela, Mexico, and many more.

The manufacturing facilities are located in Bordon (U.K.), Kalyani (India) and Baddi (India). These plants are approved by the regulatory bodies of countries like Brazil, Colombia, Malaysia, Turkey, Pakistan, Ukraine, Sudan, Belarus Hungary, Jordan, Zimbabwe, Yemen.

Products

APIs- It manufactures Active Pharmaceutical Ingredients (API) for anti cancer, drug intermediate, calcium regulator, muscle relaxant, Analgesic and many more.

Oncology- Under this it has created drugs like Intaxel, Nanoxel.

Other range of generic products offered by Fresenius Kabi Oncology includes, Taxane Analogues, Alkylating Agents, Anti-Metabolites, Cytostatic Antibiotics, Cytostatic hormone therapies.